{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:23:30Z","timestamp":1782411810181,"version":"3.54.5"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T00:00:00Z","timestamp":1310515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00213-011-2394-1","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T03:55:00Z","timestamp":1310442900000},"page":"727-736","source":"Crossref","is-referenced-by-count":41,"title":["Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients"],"prefix":"10.1007","volume":"219","author":[{"name":"Genetic Risk and Outcome in Psychosis (GROUP) investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P.","family":"Koning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Vehof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibert","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Wilffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmar","family":"Al Hadithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Snieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,13]]},"reference":[{"key":"2394_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.biopsych.2009.08.036","volume":"67","author":"K Aberg","year":"2010","unstructured":"Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, del Miller D, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ (2010) Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67:279\u2013282","journal-title":"Biol Psychiatry"},{"key":"2394_CR2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajmg.b.30746","volume":"147B","author":"AF Al Hadithy","year":"2008","unstructured":"Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, Matroos GE, van Os J, Hoek HW, van Harten PN (2008) Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 147B:890\u2013897","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2394_CR3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.pnpbp.2009.01.010","volume":"33","author":"AF Al Hadithy","year":"2009","unstructured":"Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Wilffert B, Bruggeman R, Loonen AJ (2009) Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 33:475\u2013481","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2394_CR4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hup.1087","volume":"25","author":"AF Al Hadithy","year":"2010","unstructured":"Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Wilffert B, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Loonen AJ (2010) Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 25:84\u201391","journal-title":"Hum Psychopharmacol"},{"key":"2394_CR5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YPG.0b013e3283328dcd","volume":"19","author":"I Al-Janabi","year":"2009","unstructured":"Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glaser PE, Clark D, de Leon J (2009) Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 19:305\u2013311","journal-title":"Psychiatr Genet"},{"key":"2394_CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00213-009-1627-z","volume":"206","author":"A Alkelai","year":"2009","unstructured":"Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009) Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 206:491\u2013499","journal-title":"Psychopharmacology (Berl)"},{"key":"2394_CR7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","volume":"67","author":"NC Andreasen","year":"2010","unstructured":"Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67:255\u2013262","journal-title":"Biol Psychiatry"},{"key":"2394_CR8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/6.4.577","volume":"6","author":"T Arinami","year":"1997","unstructured":"Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577\u2013582","journal-title":"Hum Mol Genet"},{"key":"2394_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","volume":"12","author":"MJ Arranz","year":"2007","unstructured":"Arranz MJ, de Leon J (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707\u2013747","journal-title":"Mol Psychiatry"},{"key":"2394_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2006.01.010","volume":"83","author":"PR Bakker","year":"2006","unstructured":"Bakker PR, van Harten PN, van Os J (2006) Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83:185\u2013192","journal-title":"Schizophr Res"},{"key":"2394_CR11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4002142","volume":"13","author":"PR Bakker","year":"2008","unstructured":"Bakker PR, van Harten PN, van Os J (2008) Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 13:544\u2013556","journal-title":"Mol Psychiatry"},{"key":"2394_CR12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672\u2013676","journal-title":"Br J Psychiatry"},{"key":"2394_CR13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/schbul\/17.3.483","volume":"17","author":"JJ Bartko","year":"1991","unstructured":"Bartko JJ (1991) Measurement and reliability: statistical thinking considerations. Schizophr Bull 17:483\u2013489","journal-title":"Schizophr Bull"},{"key":"2394_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/brain\/awn248","volume":"132","author":"A Bertolino","year":"2009","unstructured":"Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, Di Giorgio A, Taurisano P, Papp A, Pinsonneault J, Wang D, Nardini M, Popolizio T, Sadee W (2009) Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 132:417\u2013425","journal-title":"Brain"},{"key":"2394_CR15","first-page":"1497","volume-title":"Psychopharmacology: the fourth generation of progress","author":"DE Casey","year":"1995","unstructured":"Casey DE (1995) Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1497\u20131502"},{"issue":"Suppl 9","key":"2394_CR16","first-page":"25","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65(Suppl 9):25\u201328","journal-title":"J Clin Psychiatry"},{"key":"2394_CR17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1996.01830040049009","volume":"53","author":"MH Chakos","year":"1996","unstructured":"Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53:313\u2013319","journal-title":"Arch Gen Psychiatry"},{"key":"2394_CR18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","volume":"21","author":"CU Correll","year":"2008","unstructured":"Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151\u2013156","journal-title":"Curr Opin Psychiatry"},{"key":"2394_CR19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","volume":"161","author":"CU Correll","year":"2004","unstructured":"Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1\u00a0year studies. Am J Psychiatry 161:414\u2013425","journal-title":"Am J Psychiatry"},{"key":"2394_CR20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000177546.34799.af","volume":"25","author":"J Leon de","year":"2005","unstructured":"de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ (2005) Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 25:448\u2013456","journal-title":"J Clin Psychopharmacol"},{"key":"2394_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddg055","volume":"12","author":"J Duan","year":"2003","unstructured":"Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205\u2013216","journal-title":"Hum Mol Genet"},{"key":"2394_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8","volume":"96","author":"P Eichhammer","year":"2000","unstructured":"Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, Frick U, Klein HE, Rohrmeier T (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen\u2019s study on DRD3 and tardive dyskinesia. Am J Med Genet 96:187\u2013191","journal-title":"Am J Med Genet"},{"key":"2394_CR23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/106002809703101114","volume":"31","author":"EJ Frackiewicz","year":"1997","unstructured":"Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR (1997) Ethnicity and antipsychotic response. Ann Pharmacother 31:1360\u20131369","journal-title":"Ann Pharmacother"},{"key":"2394_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10401230209147398","volume":"14","author":"J Gerlach","year":"2002","unstructured":"Gerlach J (2002) Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14:47\u201357","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl 4","key":"2394_CR25","first-page":"15","volume":"61","author":"WM Glazer","year":"2000","unstructured":"Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15\u201320","journal-title":"J Clin Psychiatry"},{"key":"2394_CR26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FPC.0b013e32800ffbb4","volume":"17","author":"L Greenbaum","year":"2007","unstructured":"Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, Katz E, Kotler M, Olender T, Deshpande SN, Lancet D, Ben-Asher E, Lerer B (2007) Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 17:519\u2013528","journal-title":"Pharmacogenet Genomics"},{"key":"2394_CR27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/tpj.2008.6","volume":"9","author":"L Greenbaum","year":"2009","unstructured":"Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K, Korner M, Lancet D, Ben-Asher E, Lerer B (2009) Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3\u2032-untranslated region. Pharmacogenomics J 9:103\u2013110","journal-title":"Pharmacogenomics J"},{"key":"2394_CR28","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/mds.23377","volume":"25","author":"L Greenbaum","year":"2010","unstructured":"Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B (2010) Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 25:2809\u20132817","journal-title":"Mov Disord"},{"issue":"2","key":"2394_CR29","first-page":"138","volume":"68","author":"GROUP","year":"2010","unstructured":"GROUP (2010) Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry 68(2):138\u2013147","journal-title":"Arch Gen Psychiatry"},{"key":"2394_CR30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-006-0622-x","volume":"190","author":"A Gunes","year":"2007","unstructured":"Gunes A, Scordo MG, Jaanson P, Dahl ML (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) 190:479\u2013484","journal-title":"Psychopharmacology (Berl)"},{"key":"2394_CR31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00228-007-0450-x","volume":"64","author":"A Gunes","year":"2008","unstructured":"Gunes A, Dahl ML, Spina E, Scordo MG (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64:477\u2013482","journal-title":"Eur J Clin Pharmacol"},{"key":"2394_CR32","unstructured":"Guy E (1976) Abnormal Involuntary Movement Scale, ECDEU assessment manual for psychopharmacology. National institute of mental Health, U.S. Department Health and Human Services, National institute of mental Health, U.S. Department Health and Human Services"},{"key":"2394_CR33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","volume":"63","author":"C Guzey","year":"2007","unstructured":"Guzey C, Scordo MG, Spina E, Landsem VM, Spigset O (2007) Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 63:233\u2013241","journal-title":"Eur J Clin Pharmacol"},{"key":"2394_CR34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajmg.10045","volume":"105","author":"H Hori","year":"2001","unstructured":"Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J (2001) Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 105:774\u2013778","journal-title":"Am J Med Genet"},{"key":"2394_CR35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/FPC.0b013e3282f70492","volume":"18","author":"T Inada","year":"2008","unstructured":"Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, Takahashi N, Ozaki N, Arinami T (2008) Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 18:317\u2013323","journal-title":"Pharmacogenet Genomics"},{"key":"2394_CR36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","volume":"4","author":"EG Jonsson","year":"1999","unstructured":"Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290\u2013296","journal-title":"Mol Psychiatry"},{"key":"2394_CR37","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1002\/sim.3420","volume":"27","author":"AL Jorgensen","year":"2008","unstructured":"Jorgensen AL, Williamson PR (2008) Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 27:6547\u20136569","journal-title":"Stat Med"},{"key":"2394_CR38","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 371:1085\u20131097","journal-title":"Lancet"},{"key":"2394_CR39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.mp.4001054","volume":"7","author":"R Kaiser","year":"2002","unstructured":"Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J (2002) Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7:695\u2013705","journal-title":"Mol Psychiatry"},{"key":"2394_CR40","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/appi.ajp.163.8.1316","volume":"163","author":"JM Kane","year":"2006","unstructured":"Kane JM (2006) Tardive dyskinesia circa 2006. Am J Psychiatry 163:1316\u20131318","journal-title":"Am J Psychiatry"},{"key":"2394_CR41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900026304","volume":"12","author":"JM Kane","year":"2007","unstructured":"Kane JM (2007) Treatment adherence and long-term outcomes. CNS Spectr 12:21\u201326","journal-title":"CNS Spectr"},{"key":"2394_CR42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","volume":"39","author":"JM Kane","year":"1982","unstructured":"Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473\u2013481","journal-title":"Arch Gen Psychiatry"},{"key":"2394_CR43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S (2009) Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70:627\u2013643","journal-title":"J Clin Psychiatry"},{"key":"2394_CR44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hup.988","volume":"24","author":"SG Kang","year":"2009","unstructured":"Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L (2009) Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 24:55\u201360","journal-title":"Hum Psychopharmacol"},{"key":"2394_CR45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","volume":"27","author":"S Kapur","year":"2003","unstructured":"Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081\u20131090","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2394_CR46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","volume":"156","author":"S Kapur","year":"1999","unstructured":"Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286\u2013293","journal-title":"Am J Psychiatry"},{"key":"2394_CR47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"2394_CR48","first-page":"211","volume":"42","author":"M Laruelle","year":"1998","unstructured":"Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211\u2013221","journal-title":"Q J Nucl Med"},{"key":"2394_CR49","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511543944","volume-title":"Pharmacogenetics of psychotropic drugs","author":"B Lerer","year":"2002","unstructured":"Lerer B (2002) Pharmacogenetics of psychotropic drugs. Cambridge University Press, Cambridge"},{"key":"2394_CR50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0893-133X(02)00293-2","volume":"27","author":"B Lerer","year":"2002","unstructured":"Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27:105\u2013119","journal-title":"Neuropsychopharmacology"},{"key":"2394_CR51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/pr.107.00107","volume":"60","author":"JA Lieberman","year":"2008","unstructured":"Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358\u2013403","journal-title":"Pharmacol Rev"},{"issue":"Suppl 1","key":"2394_CR52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-2000-7672","volume":"33","author":"M Marsalek","year":"2000","unstructured":"Marsalek M (2000) Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 33(Suppl 1):14\u201333","journal-title":"Pharmacopsychiatry"},{"key":"2394_CR53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S003329170003960X","volume":"10","author":"CD Marsden","year":"1980","unstructured":"Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55\u201372","journal-title":"Psychol Med"},{"key":"2394_CR54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mds.870090112","volume":"9","author":"P Martinez-Martin","year":"1994","unstructured":"Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F (1994) Unified Parkinson\u2019s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 9:76\u201383","journal-title":"Mov Disord"},{"key":"2394_CR55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4088\/PCC.08r00612","volume":"11","author":"PS Masand","year":"2009","unstructured":"Masand PS, Roca M, Turner MS, Kane JM (2009) Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 11:147\u2013154","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2394_CR56","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79\u2013104","journal-title":"Mol Psychiatry"},{"key":"2394_CR57","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","volume":"50","author":"H Morgenstern","year":"1993","unstructured":"Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50:723\u2013733","journal-title":"Arch Gen Psychiatry"},{"key":"2394_CR58","first-page":"851","volume":"11","author":"F Ng","year":"2008","unstructured":"Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851\u2013876","journal-title":"Int J Neuropsychopharmacol"},{"key":"2394_CR59","first-page":"505","volume":"9","author":"T Pohjalainen","year":"1999","unstructured":"Pohjalainen T, Nagren K, Syvalahti EK, Hietala J (1999) The dopamine D2 receptor 5\u2032-flanking variant,\u2212141C Ins\/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 9:505\u2013509","journal-title":"Pharmacogenetics"},{"key":"2394_CR60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.schres.2009.06.010","volume":"113","author":"S Potvin","year":"2009","unstructured":"Potvin S, Blanchet P, Stip E (2009) Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res 113:181\u2013188","journal-title":"Schizophr Res"},{"key":"2394_CR61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1021648128758","volume":"28","author":"T Ritchie","year":"2003","unstructured":"Ritchie T, Noble EP (2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28:73\u201382","journal-title":"Neurochem Res"},{"key":"2394_CR62","doi-asserted-by":"crossref","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S (2011) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. doi: 10.1093\/schbul\/sbq042","DOI":"10.1093\/schbul\/sbq042"},{"key":"2394_CR63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psc.2004.10.004","volume":"28","author":"PS Sachdev","year":"2005","unstructured":"Sachdev PS (2005) Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 28:255\u2013274","journal-title":"Psychiatr Clin North Am"},{"key":"2394_CR64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486\u2013487","journal-title":"Arch Gen Psychiatry"},{"key":"2394_CR65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","volume":"31","author":"JC Schwartz","year":"2000","unstructured":"Schwartz JC, Diaz J, Pilon C, Sokoloff P (2000) Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 31:277\u2013287","journal-title":"Brain Res Brain Res Rev"},{"key":"2394_CR66","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s002130000521","volume":"152","author":"RH Segman","year":"2000","unstructured":"Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B (2000) Association between the serotonin 2\u00a0C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152:408\u2013413","journal-title":"Psychopharmacology (Berl)"},{"key":"2394_CR67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.mp.4000842","volume":"6","author":"RH Segman","year":"2001","unstructured":"Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6:225\u2013229","journal-title":"Mol Psychiatry"},{"key":"2394_CR68","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/379378","volume":"73","author":"M Stephens","year":"2003","unstructured":"Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162\u20131169","journal-title":"Am J Hum Genet"},{"key":"2394_CR69","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1086\/319501","volume":"68","author":"M Stephens","year":"2001","unstructured":"Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978\u2013989","journal-title":"Am J Hum Genet"},{"key":"2394_CR70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0006-8993(97)01078-0","volume":"779","author":"M Suzuki","year":"1998","unstructured":"Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G (1998) D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779:58\u201374","journal-title":"Brain Res"},{"key":"2394_CR71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10401239709147773","volume":"9","author":"JR Swartz","year":"1997","unstructured":"Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K (1997) Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiatry 9:53\u201359","journal-title":"Ann Clin Psychiatry"},{"key":"2394_CR72","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/appi.ajp.163.8.1438","volume":"163","author":"DE Tenback","year":"2006","unstructured":"Tenback DE, van Harten PN, Slooff CJ, van Os J (2006) Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 163:1438\u20131440","journal-title":"Am J Psychiatry"},{"issue":"16","key":"2394_CR73","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/mds.22707","volume":"24","author":"DE Tenback","year":"2009","unstructured":"Tenback DE, van Harten PN, van Os J (2009) Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 24(16):2309\u20132315","journal-title":"Mov Disord"},{"key":"2394_CR74","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ajp.155.9.1207","volume":"155","author":"G Tsai","year":"1998","unstructured":"Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT (1998) Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 155:1207\u20131213","journal-title":"Am J Psychiatry"},{"key":"2394_CR75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tig.2003.08.003","volume":"19","author":"EJ Oord van den","year":"2003","unstructured":"van den Oord EJ, Sullivan PF (2003a) False discoveries and models for gene discovery. Trends Genet 19:537\u2013542","journal-title":"Trends Genet"},{"key":"2394_CR76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000076393","volume":"56","author":"EJ Oord van den","year":"2003","unstructured":"van den Oord EJ, Sullivan PF (2003b) A framework for controlling false discovery rates and minimizing the amount of genotyping in the search for disease mutations. Hum Hered 56:188\u2013199","journal-title":"Hum Hered"},{"key":"2394_CR77","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.6132447","volume":"220","author":"JL Waddington","year":"1983","unstructured":"Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6\u00a0months of neuroleptic treatment. Science 220:530\u2013532","journal-title":"Science"},{"key":"2394_CR78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0169-328X(94)90133-3","volume":"24","author":"C Waeber","year":"1994","unstructured":"Waeber C, Palacios JM (1994) Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia. Brain Res Mol Brain Res 24:199\u2013209","journal-title":"Brain Res Mol Brain Res"},{"key":"2394_CR79","doi-asserted-by":"crossref","unstructured":"Warrens M (2010) Inequalities between multi-rater kappas. Adv Data Anal Classif: 271\u2013286","DOI":"10.1007\/s11634-010-0073-4"},{"key":"2394_CR80","unstructured":"Weiden P (1994) Neuroleptic-induced parkinsonism. American Psychiatric Association (APA), American Psychiatric Association (APA)"},{"issue":"Suppl 14","key":"2394_CR81","first-page":"14","volume":"68","author":"PJ Weiden","year":"2007","unstructured":"Weiden PJ (2007) Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 68(Suppl 14):14\u201319","journal-title":"J Clin Psychiatry"},{"key":"2394_CR82","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/0269881108091594","volume":"23","author":"B Wilffert","year":"2009","unstructured":"Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, van Os J, Bruggeman R, Brouwers JR, van Harten PN (2009) The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 23:652\u2013659","journal-title":"J Psychopharmacol"},{"key":"2394_CR83","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1745-7254.2006.00355.x","volume":"27","author":"SN Wu","year":"2006","unstructured":"Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L (2006) Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 27:966\u2013970","journal-title":"Acta Pharmacol Sin"},{"key":"2394_CR84","first-page":"639","volume":"10","author":"CC Zai","year":"2007","unstructured":"Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL (2007) Association study of tardive dyskinesia and 12 DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 10:639\u2013651","journal-title":"Int J Neuropsychopharmacol"},{"key":"2394_CR85","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/15622975.2010.486043","volume":"11","author":"CC Zai","year":"2010","unstructured":"Zai CC, Tiwari AK, Muller DJ, de Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL (2010) The catechol-O-methyl-transferase gene in tardive dyskinesia. World J Biol Psychiatry 11:803\u2013812","journal-title":"World J Biol Psychiatry"},{"key":"2394_CR86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000057986","volume":"53","author":"DV Zaykin","year":"2002","unstructured":"Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG (2002) Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 53:79\u201391","journal-title":"Hum Hered"},{"key":"2394_CR87","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","volume":"167","author":"JP Zhang","year":"2010","unstructured":"Zhang JP, Lencz T, Malhotra AK (2010) D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167:763\u2013772","journal-title":"Am J Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2394-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2394-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T16:54:20Z","timestamp":1712595260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2394-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,13]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["2394"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2394-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,13]]}}}